Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
Transfusional iron overload is a major target in the care of patients with transfusion-
dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver …
dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver …
Iron chelation in thalassemia major
C Borgna-Pignatti, M Marsella - Clinical therapeutics, 2015 - Elsevier
Purpose Iron chelation has improved survival and quality of life of patients with thalassemia
major. there are currently 3 commercially available iron-chelating drugs with different …
major. there are currently 3 commercially available iron-chelating drugs with different …
How I treat and manage strokes in sickle cell disease
AA Kassim, NA Galadanci, S Pruthi… - Blood, The Journal of …, 2015 - ashpublications.org
Neurologic complications are a major cause of morbidity and mortality in sickle cell disease
(SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening …
(SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening …
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
Y Aydinok, A Kattamis, MD Cappellini… - Blood, The Journal …, 2015 - ashpublications.org
Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron
concentrations (LIC), although some patients may require intensive chelation for a limited …
concentrations (LIC), although some patients may require intensive chelation for a limited …
Current and future treatment strategies for iron overload cardiomyopathy
S Wongjaikam, S Kumfu, SC Chattipakorn… - European journal of …, 2015 - Elsevier
Iron overload cardiomyopathy is the major cause of death in transfusion-dependent
thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators …
thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators …
Combination therapy–deferasirox and deferoxamine–in thalassemia major patients in emerging countries with limited resources
N Arandi, S Haghpanah, S Safaei, Z Zahedi… - Transfusion …, 2015 - Wiley Online Library
Background The problem of iron‐overload observed in thalassemia patients can be
overcome using chelating agents such as deferiprone (Ferroprox®), deferasirox (Exjade®) …
overcome using chelating agents such as deferiprone (Ferroprox®), deferasirox (Exjade®) …
Efficacy of oral deferasirox by twice-daily dosing in patients with transfusion-dependent beta thalassemia
E Salehifar, H Karami, M Kosaryan… - … of Medical Sciences, 2015 - jmums.mazums.ac.ir
Background and purpose: Patients with Beta thalassemia major need consistent blood
transfusion from early years of life. Deferasirox is used as an oral chelating agent (once …
transfusion from early years of life. Deferasirox is used as an oral chelating agent (once …
[PDF][PDF] La Bêta-thalassémie: Étude d'une cohorte de cas colligés au Laboratoire de Biochimie et de Toxicologie de l'Hôpital Militaire d'Instruction Mohamed V (HMIMV) …
YI Ramatou - 2015 - toubkal.imist.ma
Pour l'Obtention du Doctorat en Pharmacie Page 1 UNIVERSITE MOHAMMED V RABAT
FACULTE DE MEDECINE ET DE PHARMACIE -RABAT- ANNEE: 2015 THESE N:18 La …
FACULTE DE MEDECINE ET DE PHARMACIE -RABAT- ANNEE: 2015 THESE N:18 La …
Efficacy of Oral Deferasirox by Twice-daily Dosing in Patients with Transfusion-dependent Beta Thalassemia.
ابراهيم صالحي فر, حسين كرمي… - … of Medical Sciences …, 2015 - search.ebscohost.com
Background and purpose: Patients with Beta thalassemia major need consistent blood
transfusion from early years of life. Deferasirox is used as an oral chelating agent (once …
transfusion from early years of life. Deferasirox is used as an oral chelating agent (once …
ارزیابی اثر بخشی دفرازیروکس خوراکی به صورت دوبار در روز در بیماران بتاتالاسمی وابسته به تزریق خون
صالحی فر ابراهیم, کرمی حسین, کوثریان مهرنوش… - 2015 - sid.ir
سابقه و هدف: بیماران مبتلا به بتاتالاسمی ماژور از سال های ابتدایی زندگی به تزریق مداوم خون
نیاز دارند. دفرازیروکس یک شلات کننده خوراکی است که به صورت یک بار در روز برای دفع …
نیاز دارند. دفرازیروکس یک شلات کننده خوراکی است که به صورت یک بار در روز برای دفع …